The Chemours (CC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.42
- EPS estimate
- $0.50
- EPS surprise
- −15.39%
- Revenue surprise
- −3.84%
- Revenue
- $1.6B
- Revenue estimate
- $1.7B
- Reported
- Aug 4, 2026
Chemours reported Q2 2026 results on August 4, 2026. Earnings per share were $0.42, missing the $0.50 estimate by 15.39%. Revenue of $1.6 billion fell 3.84% short of the $1.7 billion estimate. Compared with Q2 2025, EPS fell about 28% from $0.58, while revenue was unchanged at $1.6 billion.
The table shows a long decline in earnings. Annual EPS fell from $4.59 in 2022 to $3.02 in 2023, $1.21 in 2024 and $0.96 in 2025. The first half of 2026 totals $0.47, about 34% below the $0.71 of a year earlier. The high in the table is $1.89 per share in Q2 2022, and the low is Q4 2022, a break-even quarter at $0.00. Annual revenue slipped from $6.8 billion in 2022 to $6.0 billion in 2023 and $5.8 billion in both 2024 and 2025. Chemours beat the EPS estimate 11 times and missed 9 times over the last 20 quarters.
Chemours reported third-quarter results between October 25 and November 6 in each of the past five years. That points to late October or early November 2026 for the Q3 report. It will show whether EPS continues to trail the year-earlier quarter, as in the last four reports.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.50 | $0.42 | −15.39% | $1.6B | SEC |
| Q1 2026 | May 5, 2026 | −$0.04 | $0.05 | +227.23% | $1.4B | SEC |
| Q4 2025 | Feb 19, 2026 | $0.07 | $0.05 | −31.22% | $1.3B | SEC |
| Q3 2025 | Nov 6, 2025 | $0.24 | $0.20 | −15.90% | $1.5B | SEC |
| Q2 2025 | Aug 5, 2025 | $0.46 | $0.58 | +27.14% | $1.6B | SEC |
| Q1 2025 | May 6, 2025 | $0.20 | $0.13 | −33.84% | $1.4B | SEC |
| Q4 2024 | Feb 18, 2025 | $0.12 | $0.11 | −9.24% | $1.4B | SEC |
| Q3 2024 | Nov 4, 2024 | $0.29 | $0.40 | +40.25% | $1.5B | SEC |
| Q2 2024 | Aug 1, 2024 | $0.57 | $0.38 | −33.50% | $1.5B | SEC |
| Q1 2024 | Apr 30, 2024 | $0.18 | $0.32 | +76.60% | $1.4B | SEC |
| Q4 2023 | Feb 29, 2024 | $0.27 | $0.31 | +15.24% | $1.4B | SEC |
| Q3 2023 | Oct 26, 2023 | $0.69 | $0.63 | −8.44% | $1.5B | SEC |
| Q2 2023 | Jul 28, 2023 | $1.08 | $1.10 | +1.93% | $1.6B | SEC |
| Q1 2023 | Apr 27, 2023 | $0.46 | $0.98 | +113.51% | $1.5B | SEC |
| Q4 2022 | Feb 9, 2023 | $0.10 | $0.00 | −100.00% | $1.3B | SEC |
| Q3 2022 | Oct 25, 2022 | $1.04 | $1.24 | +18.80% | $1.8B | SEC |
| Q2 2022 | Jul 28, 2022 | $1.41 | $1.89 | +34.13% | $1.9B | SEC |
| Q1 2022 | May 2, 2022 | $0.91 | $1.46 | +59.63% | $1.8B | SEC |
| Q4 2021 | Feb 10, 2022 | $0.89 | $0.81 | −8.71% | $1.6B | SEC |
| Q3 2021 | Nov 4, 2021 | $1.01 | $1.27 | +26.29% | $1.7B | SEC |
Quarterly revenue
Frequently asked questions
When did The Chemours (CC) last report earnings?
The Chemours last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did CC beat earnings estimates?
No. The Chemours reported EPS of $0.42 for Q2 2026 against a $0.50 estimate — a 15.39% miss.
How much revenue did CC report last quarter?
The Chemours reported $1.6B in revenue for Q2 2026, against a consensus estimate of $1.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.